2Sergio R,Giuseppe B,Daniele F. Prognostic vs predictive molecular biomarkers in colorectal cancer:is KRAS and BRAF wild type status required anti-EGFR therapy[J].Cancer Treatment Reviews,2010.S56-S61.
2Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small- cell lung cancer treated with chemotherapy alone and in combination with erlotinib [ J ]. J Clin Oncol, 2005, 23 (25) : 5900 -5909.
3Jackman DM, Cioffredi L, Sequist LV, et al. Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib [J]. J Clin Oncol, 2008, 26(15S) : 8035.
4Zhang Xiaozhu, Chang Alex. Molecular predictors of EG- FR-TKI sensitivity in advanced non-small cell lung cancer [J]. Int J Med Sci, 2008, 5(4) : 209 -217.
5Le Tourneau C, Vidal L, Siu LL. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents [ J ]. Drug Resist Updat, 2008, 11 (3) :99 - 109.
6Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/ PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab[ J]. Cancer Res, 2008, 68 : 1953 - 1961.
7Pirker R, Szczesna A, yon Pawel J,et al. FLEX:A randomized, multicenter, phase m study of cetuximabin combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer(NSCLC) [J]. J Clin Oncol, 2008, 26(15S) : 3.
8Sousa SF, Fernandes PA, Ramos MJ. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem [ J ]. Curr Med Chem, 2008, 15 ( 15 ) : 1478 - 1492.
9Mark RP, Adrienne DC. Geranylgeranyltransferase I as a target for anti-cancer drugs[J]. J Clin Invest, 2007, 117: 1223 - 1225.
10Adjei AA. K-RAS as a target for lung cancer therapy[ J]. J Thorac Oncol, 2008, 3 (6 Suppl 2) : 160 - 163.
